Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Arthralgia and Depression Outcome Measures
2.3. Plasma Sample Collection and Preparation
2.4. Reverse Phase Chromatography with UPLC–MS
2.5. Statistical Analysis
3. Results
3.1. Participants and Characteristics
3.2. Change in Symptom Scores
3.3. Correlation between Oxylipins and Symptom Scores at Baseline
3.4. Change in PUFAs and Oxylipins
3.5. Baseline Oxylipins Predict Changes in Symptom Scores
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Goss, P.E.; Ingle, J.N.; Pritchard, K.I.; Robert, N.J.; Muss, H.; Gralow, J.; Gelmon, K.; Whelan, T.; Strasser-Weippl, K.; Rubin, S.; et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N. Engl. J. Med. 2016, 375, 209–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hershman, D.L.; Kushi, L.; Shao, T.; Buono, D.; Kershenbaum, A.; Tsai, W.-Y.; Fehrenbacher, L.; Gomez, S.L.; Miles, S.; Neugut, A.I. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J. Clin. Oncol. 2010, 28, 4120–4128. [Google Scholar] [CrossRef] [PubMed]
- Hershman, D.L.; Shao, T.; Kushi, L.H.; Buono, D.; Tsai, W.Y.; Fehrenbacher, L.; Kwan, M.; Gomez, S.L.; Neugut, A.I. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res. Treat. 2011, 126, 529–537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Borrie, A.E.; Kim, R.B. Molecular basis of aromatase inhibitor associated arthralgia: Known and potential candidate genes and associated biomarkers. Expert Opin. Drug Metab. Toxicol. 2017, 13, 149–156. [Google Scholar] [CrossRef] [PubMed]
- Henry, N.L.; Conlon, A.; Kidwell, K.M.; Griffith, K.; Smerage, J.B.; Schott, A.F.; Hayes, D.F.; Williams, D.A.; Clauw, D.J.; Harte, S.E. Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor–Treated Women With Early-Stage Breast Cancer. J. Pain 2014, 15, 468–475. [Google Scholar] [CrossRef] [Green Version]
- Henry, N.L.; Giles, J.T.; Ang, D.; Mohan, M.; Dadabhoy, D.; Robarge, J.; Hayden, J.; Lemler, S.; Shahverdi, K.; Powers, P.; et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res. Treat. 2007, 111, 365–372. [Google Scholar] [CrossRef] [Green Version]
- Coleman, R.; Bolten, W.; Lansdown, M.; Dale, S.; Jackisch, C.; Merkel, D.; Maass, N.; Hadji, P. Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat. Rev. 2008, 34, 275–282. [Google Scholar] [CrossRef]
- Martinez, J.A.; Wertheim, B.C.; Roe, D.J.; Chalasani, P.; Cohen, J.; Baer, L.; Chow, H.-H.S.; Stopeck, A.T.; Thompson, P.A. Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer. Breast Cancer Res. Treat. 2022, 192, 113–122. [Google Scholar] [CrossRef]
- Henry, N.L.; Pchejetski, D.; A’Hern, R.; Nguyen, A.T.; Charles, P.; Waxman, J.; Li, L.; Storniolo, A.M.; Hayes, D.F.; A Flockhart, D.; et al. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study. Br. J. Cancer 2010, 103, 291–296. [Google Scholar] [CrossRef] [Green Version]
- Saini, R.K.; Keum, Y.-S. Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance—A review. Life Sci. 2018, 203, 255–267. [Google Scholar] [CrossRef]
- Multon, S.; Pardutz, A.; Mosen, J.; Hua, M.T.; Defays, C.; Honda, S.-I.; Harada, N.; Bohotin, C.; Franzen, R.; Schoenen, J. Lack of estrogen increases pain in the trigeminal formalin model: A behavioural and immunocytochemical study of transgenic ArKO mice. Pain 2005, 114, 257–265. [Google Scholar] [CrossRef] [PubMed]
- Hunter, D.A.; Barr, G.A.; Shivers, K.-Y.; Amador, N.; Jenab, S.; Inturrisi, C.; Quinones-Jenab, V. Interactions of estradiol and NSAIDS on carrageenan-induced hyperalgesia. Brain Res. 2011, 1382, 181–188. [Google Scholar] [CrossRef] [Green Version]
- Hunter, D.A.; Barr, G.A.; Amador, N.; Shivers, K.-Y.; Kemen, L.; Kreiter, C.M.; Jenab, S.; Inturrisi, C.E.; Quinones-Jenab, V. Estradiol-induced antinociceptive responses on formalin-induced nociception are independent of COX and HPA activation. Synapse 2010, 65, 643–651. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martinez, J.A.; Yang, J.; Wertheim, B.C.; Roe, D.J.; Schriewer, A.; Lance, P.; Alberts, D.S.; Hammock, B.D.; Thompson, P.A. Celecoxib use and circulating oxylipins in a colon polyp prevention trial. PLoS ONE 2018, 13, e0196398. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rodríguez-Carrio, J.; Coras, R.; Alperi-López, M.; López, P.; Ulloa, C.; Ballina-García, F.J.; Armando, A.M.; Quehenberger, O.; Guma, M.; Suárez, A. Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis. Arthritis Rheumatol. 2020, 73, 401–413. [Google Scholar] [CrossRef] [PubMed]
- Gouveia-Figueira, S.; Nording, M.L.; Gaida, J.E.; Forsgren, S.; Alfredson, H.; Fowler, C.J. Serum Levels of Oxylipins in Achilles Tendinopathy: An Exploratory Study. PLoS ONE 2015, 10, e0123114. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.; Yang, G.; Khan, M.; Stone, D.; Woo, S.L.-Y.; Wang, J.H.-C. Inflammatory Response of Human Tendon Fibroblasts to Cyclic Mechanical Stretching. Am. J. Sports Med. 2004, 32, 435–440. [Google Scholar] [CrossRef] [PubMed]
- Martinez, J.A.; Taljanovic, M.S.; Witte, R.S.; Zuniga, A.A.N.; Wertheim, B.C.; Kwoh, C.K.; Goldstein, B.A.; Roe, D.J.; Chalasani, P. Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor-induced joint pain: A pilot study. J. Ultrason. 2021, 21, e1–e6. [Google Scholar] [CrossRef]
- Martinez, J.A.; Taljanovic, M.S.; Zuniga, A.A.N.; Wertheim, B.C.; Roe, D.J.; Ehsani, S.; Jiralerspong, S.; Segar, J.; Chalasani, P. Feasibility Trial to Evaluate Tendon Stiffness Obtained from Shear Wave Elastography Imaging as a Biomarker of Aromatase Inhibitor-Induced Arthralgias. J. Clin. Med. 2022, 11, 1067. [Google Scholar] [CrossRef]
- Diani-Moore, S.; Papachristou, F.; Labitzke, E.; Rifkind, A.B. Induction of CYP1A and cyp2-mediated arachidonic acid epoxygenation and suppression of 20-hydroxyeicosatetraenoic acid by imidazole derivatives including the aromatase inhibitor vorozole. Drug Metab. Dispos. Biol. Fate Chem. 2006, 34, 1376–1385. [Google Scholar] [CrossRef] [Green Version]
- Russell, R.; Gori, I.; Pellegrini, C.; Kumar, R.; Achtari, C.; Canny, G.O. Lipoxin A4 is a novel estrogen receptor modulator. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2011, 25, 4326–4337. [Google Scholar]
- Domenichiello, A.F.; Sapio, M.R.; Loydpierson, A.J.; Maric, D.; Goto, T.; Horowitz, M.S.; Keyes, G.S.; Yuan, Z.-X.; Majchrzak-Hong, S.F.; Mannes, A.J.; et al. Molecular Pathways Linking Oxylipins to Nociception in Rats. J. Pain 2020, 22, 275–299. [Google Scholar] [CrossRef] [PubMed]
- Stanton, A.L.; Bernaards, C.A.; Ganz, P.A. The BCPT symptom scales: A measure of physical symptoms for women diagnosed with or at risk for breast cancer. Gynecol. Oncol. 2005, 97, 448–456. [Google Scholar] [CrossRef] [PubMed]
- Swenson, K.K.; Nissen, M.J.; Henly, S.J.; Maybon, L.; Pupkes, J.; Zwicky, K.; Tsai, M.L.; Shapiro, A.C. Identification of Tools to Measure Changes in Musculoskeletal Symptoms and Physical Functioning in Women With Breast Cancer Receiving Aromatase Inhibitors. Oncol. Nurs. Forum 2013, 40, 549–557. [Google Scholar] [CrossRef] [Green Version]
- Bellamy, N.; Buchanan, W.W.; Goldsmith, C.H.; Campbell, J.; Stitt, L.W. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 1988, 15, 1833–1840. [Google Scholar]
- Chen, L.; Lin, C.C.; Huang, T.W.; Kuan, Y.C.; Huang, Y.H.; Chen, H.C.; Kao, C.Y.; Su, C.M.; Tam, K.W. Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials. Breast 2017, 33, 132–138. [Google Scholar] [CrossRef]
- Kroenke, K.; Spitzer, R.L.; Williams, J.B. The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16, 606–613. [Google Scholar] [CrossRef]
- Burgess, C.; Cornelius, V.; Love, S.; Graham, J.; Richards, M.; Ramirez, A. Depression and anxiety in women with early breast cancer: Five year observational cohort study. BMJ 2005, 330, 702. [Google Scholar] [CrossRef] [Green Version]
- Thompson, T.; Correll, C.U.; Gallop, K.; Vancampfort, D.; Stubbs, B. Is Pain Perception Altered in People With Depression? A Systematic Review and Meta-Analysis of Experimental Pain Research. J. Pain 2016, 17, 1257–1272. [Google Scholar] [CrossRef] [Green Version]
- Yang, J.; Schmelzer, K.; Georgi, K.; Hammock, B.D. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal. Chem. 2009, 81, 8085–8093. [Google Scholar] [CrossRef] [Green Version]
- Liu, J.Y.; Tsai, H.J.; Hwang, S.H.; Jones, P.D.; Morisseau, C.; Hammock, B.D. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br. J. Pharmacol. 2009, 156, 284–296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zivkovic, A.M.; Yang, J.; Georgi, K.; Hegedus, C.; Nording, M.L.; O’Sullivan, A.; German, J.B.; Hogg, R.J.; Weiss, R.H.; Bay, C.; et al. Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics 2012, 8, 1102–1113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shapiro, A.C.; Adlis, S.A.; Robien, K.; Kirstein, M.N.; Liang, S.; Richter, S.A.; Lerner, R.E. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Res. Treat. 2016, 155, 501–512. [Google Scholar] [CrossRef] [Green Version]
- Powell, W.S.; Rokach, J. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochim. Biophys. Acta 2015, 1851, 340–355. [Google Scholar] [CrossRef] [Green Version]
- Yu, K.; Bayona, W.; Kallen, C.B.; Harding, H.P.; Ravera, C.P.; McMahon, G.; Brown, M.; Lazar, M.A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 1995, 270, 23975–23983. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kliewer, S.A.; Sundseth, S.S.; Jones, S.A.; Brown, P.J.; Wisely, G.B.; Koble, C.S.; Devchand, P.; Wahli, W.; Willson, T.M.; Lenhard, J.M.; et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. USA 1997, 94, 4318–4323. [Google Scholar] [CrossRef] [Green Version]
- Rubin, G.L.; Zhao, Y.; Kalus, A.M.; Simpson, E.R. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy. Cancer Res. 2000, 60, 1604–1608. [Google Scholar] [PubMed]
- Huang, C.-C.; Chang, M.-T.; Leu, H.-B.; Yin, W.-H.; Tseng, W.-K.; Wu, Y.-W.; Lin, T.-H.; Yeh, H.-I.; Chang, K.-C.; Wang, J.-H.; et al. Association of Arachidonic Acid-derived Lipid Mediators with Subsequent Onset of Acute Myocardial Infarction in Patients with Coronary Artery Disease. Sci. Rep. 2020, 10, 8105. [Google Scholar] [CrossRef]
- Patwardhan, A.M.; Akopian, A.N.; Ruparel, N.B.; Diogenes, A.; Weintraub, S.T.; Uhlson, C.; Murphy, R.C.; Hargreaves, K.M. Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents. J. Clin. Investig. 2010, 120, 1617–1626. [Google Scholar] [CrossRef]
- Green, D.P.; Ruparel, S.; Roman, L.; Henry, M.A.; Hargreaves, K.M. Role of endogenous TRPV1 agonists in a postburn pain model of partial-thickness injury. Pain 2013, 154, 2512–2520. [Google Scholar] [CrossRef] [Green Version]
- Patwardhan, A.M.; Scotland, P.E.; Akopian, A.N.; Hargreaves, K.M. Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia. Proc. Natl. Acad. Sci. USA 2009, 106, 18820–18824. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruparel, S.; Green, D.; Chen, P.; Hargreaves, K.M. The cytochrome P450 inhibitor, ketoconazole, inhibits oxidized linoleic acid metabolite-mediated peripheral inflammatory pain. Mol. Pain 2012, 8, 73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, T.; Dogan, I.; Rothe, M.; Kunz, J.V.; Knauf, F.; Gollasch, M.; Luft, F.C.; Gollasch, B. Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue. Metabolites 2022, 12, 34. [Google Scholar] [CrossRef]
- Yang, X.; Yi, X.; Zhang, F.; Li, F.; Lang, L.; Ling, M.; Lai, X.; Chen, L.; Quan, L.; Fu, Y.; et al. Cytochrome P450 epoxygenase-derived EPA and DHA oxylipins 17,18-epoxyeicosatetraenoic acid and 19,20-epoxydocosapentaenoic acid promote BAT thermogenesis and WAT browning through the GPR120-AMPKalpha signaling pathway. Food Funct. 2022, 13, 1232–1245. [Google Scholar] [CrossRef] [PubMed]
- Moura-Assis, A.; Afonso, M.; de Oliveira, V.; Morari, J.; dos Santos, G.A.; Koike, M.; Lottenberg, A.M.; Catharino, R.R.; Velloso, L.A.; da Silva, A.S.R.; et al. Flaxseed oil rich in omega-3 protects aorta against inflammation and endoplasmic reticulum stress partially mediated by GPR120 receptor in obese, diabetic and dyslipidemic mice models. J. Nutr. Biochem. 2018, 53, 9–19. [Google Scholar] [CrossRef]
- Agbor, L.N.; Walsh, M.T.; Boberg, J.R.; Walker, M.K. Elevated blood pressure in cytochrome P4501A1 knockout mice is associated with reduced vasodilation to omega-3 polyunsaturated fatty acids. Toxicol. Appl. Pharmacol. 2012, 264, 351–360. [Google Scholar] [CrossRef] [Green Version]
- Sawynok, J. Topical analgesics for neuropathic pain: Preclinical exploration, clinical validation, future development. Eur. J. Pain 2014, 18, 465–481. [Google Scholar] [CrossRef]
- Cury, Y.; Picolo, G.; Gutierrez, V.P.; Ferreira, S.H. Pain and analgesia: The dual effect of nitric oxide in the nociceptive system. Nitric Oxide 2011, 25, 243–254. [Google Scholar] [CrossRef]
- Malesza, I.J.; Malesza, M.; Walkowiak, J.; Mussin, N.; Walkowiak, D.; Aringazina, R.; Bartkowiak-Wieczorek, J.; Madry, E. High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review. Cells 2021, 10, 3164. [Google Scholar] [CrossRef]
- Swanson, D.; Block, R.; Mousa, S.A. Omega-3 fatty acids EPA and DHA: Health benefits throughout life. Adv. Nutr. 2012, 3, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Boyd, J.T.; LoCoco, P.M.; Furr, A.R.; Bendele, M.R.; Tram, M.; Li, Q.; Chang, F.M.; Colley, M.E.; Samenuk, G.M.; Arris, D.A.; et al. Elevated dietary omega-6 polyunsaturated fatty acids induce reversible peripheral nerve dysfunction that exacerbates comorbid pain conditions. Nat. Metab. 2021, 3, 762–773. [Google Scholar] [CrossRef] [PubMed]
- Simopoulos, A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002, 56, 365–379. [Google Scholar] [CrossRef] [PubMed]
- Hershman, D.L.; Unger, J.M.; Crew, K.D.; Awad, D.; Dakhil, S.R.; Gralow, J.; Greenlee, H.; Lew, D.L.; Minasian, L.M.; Till, C.; et al. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. J. Clin. Oncol. 2015, 33, 1910–1917. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Median (IQR) or n (%) |
---|---|
Age at enrollment (y) | 66.0 (63.1–72.6) |
Age at diagnosis (y) | 65.6 (62.7–72.3) |
Time since diagnosis (months) | 4.7 (3.6–5.9) |
BMI (kg/m2) | 25.1 (23.0–31.3) |
Race/ethnicity | |
Non-Hispanic white | 25 (89.3%) |
Hispanic | 3 (10.7%) |
Definitive breast surgery | |
Mastectomy | 6 (21.4%) |
Lumpectomy | 22 (78.6%) |
Radiation | |
No | 9 (32.1%) |
Yes | 19 (67.9%) |
Disease stage | |
0 | 8 (28.6%) |
I | 17 (60.7%) |
II | 3 (10.7%) |
Aspirin use (low dose) | |
No | 20 (71.4%) |
Yes | 8 (28.6%) |
Pain medication (non-NSAID) | |
No | 27 (96.4%) |
Yes | 1 (3.6%) |
Subscore | Baseline n = 28 | 3 Months n = 22 | 6 Months n = 24 | p Crude a | p adj-1 b | p adj-2 c |
---|---|---|---|---|---|---|
BCPT | ||||||
Total | 0.53 ± 0.41 | 0.57 ± 0.47 | 0.64 ± 0.52 | 0.005 | 0.009 | 0.008 |
Hot flash | 0.45 ± 0.81 | 0.91 ± 0.91 | 0.98 ± 1.23 | 0.004 | 0.006 | 0.005 |
Nausea | 0.16 ± 0.31 | 0.30 ± 0.50 | 0.19 ± 0.48 | 0.831 | 0.873 | 0.864 |
Bladder control | 0.59 ± 0.89 | 0.34 ± 0.47 | 0.35 ± 0.62 | 0.342 | 0.332 | 0.321 |
Vaginal problems | 0.72 ± 0.84 | 0.62 ± 0.85 | 0.67 ± 1.09 | 0.437 | 0.442 | 0.454 |
Musculoskeletal pain | 0.81 ± 0.81 | 1.08 ± 1.10 | 1.39 ± 1.23 | <0.001 | <0.001 | <0.001 |
Cognitive problems | 0.57 ± 0.75 | 0.59 ± 0.79 | 0.51 ± 0.58 | 0.207 | 0.192 | 0.206 |
Weight problems | 0.48 ± 0.67 | 0.48 ± 0.93 | 0.56 ± 0.85 | 0.230 | 0.229 | 0.223 |
Arm problems | 0.21 ± 0.50 | 0.14 ± 0.35 | 0.08 ± 0.28 | 0.643 | 0.661 | 0.709 |
WOMAC | ||||||
Total | 11.7 ± 18.4 | 12.1 ± 18.4 | 14.3 ± 19.1 | 0.324 | 0.332 | 0.335 |
Pain | 8.0 ± 14.6 | 11.2 ± 18.7 | 12.3 ± 17.6 | 0.058 | 0.045 | 0.047 |
Stiffness | 17.9 ± 20.5 | 21.0 ± 22.9 | 27.1 ± 29.4 | 0.028 | 0.031 | 0.031 |
Physical function | 12.0 ± 21.3 | 11.4 ± 18.4 | 13.4 ± 19.5 | 0.662 | 0.677 | 0.679 |
PHQ-9 | ||||||
Total | 3.61 ± 4.65 | 2.73 ± 2.88 | 2.46 ± 2.80 | 0.212 | 0.171 | 0.176 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Martinez, J.A.; Wertheim, B.C.; Roe, D.J.; Taljanovic, M.S.; Chow, H.-H.S.; Chew, W.; Ehsani, S.; Jiralerspong, S.; Segar, J.; Chalasani, P. Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients. Metabolites 2023, 13, 452. https://doi.org/10.3390/metabo13030452
Martinez JA, Wertheim BC, Roe DJ, Taljanovic MS, Chow H-HS, Chew W, Ehsani S, Jiralerspong S, Segar J, Chalasani P. Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients. Metabolites. 2023; 13(3):452. https://doi.org/10.3390/metabo13030452
Chicago/Turabian StyleMartinez, Jessica A., Betsy C. Wertheim, Denise J. Roe, Mihra S. Taljanovic, H-H. Sherry Chow, Wade Chew, Sima Ehsani, Sao Jiralerspong, Jennifer Segar, and Pavani Chalasani. 2023. "Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients" Metabolites 13, no. 3: 452. https://doi.org/10.3390/metabo13030452